Old Ayala, Inc financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
1313 N. Market Street, Suite 5100, Wilmington, Delaware
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Ayala Pharmaceuticals, Inc. (to 1/19/2023)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275 % -66.2%
Return On Equity -309 %
Return On Assets -198 % -140%
Operating Margin -5.42 K % -384%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.8 M shares +6.35%
Common Stock, Shares, Outstanding 14.1 M shares +0.89%
Entity Public Float 37.4 M USD -18.7%
Common Stock, Value, Issued 139 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 15.4 M shares +7.29%
Weighted Average Number of Shares Outstanding, Diluted 15.4 M shares +7.29%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 692 K USD -80.3%
Cost of Revenue 602 K USD -82.8%
Research and Development Expense 27.9 M USD -6.98%
General and Administrative Expense 9.74 M USD +5.01%
Operating Income (Loss) -37.5 M USD +4.37%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -37.4 M USD +5.19%
Income Tax Expense (Benefit) 584 K USD -24.7%
Net Income (Loss) Attributable to Parent -38 M USD +5.57%
Earnings Per Share, Basic -2.46 USD/shares +12.1%
Earnings Per Share, Diluted -2.46 USD/shares +12.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.41 M USD -93.5%
Cash, Cash Equivalents, and Short-term Investments 11.5 M USD
Assets, Current 3.19 M USD -92%
Property, Plant and Equipment, Net 960 K USD -14.3%
Operating Lease, Right-of-Use Asset 1.46 M USD
Assets 7.77 M USD -81.1%
Liabilities, Current 7.54 M USD +16.4%
Operating Lease, Liability, Noncurrent 1.33 M USD
Retained Earnings (Accumulated Deficit) -149 M USD -34.2%
Stockholders' Equity Attributable to Parent -1.1 M USD -103%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.1 M USD -103%
Liabilities and Equity 7.77 M USD -81.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.5 M USD +10%
Net Cash Provided by (Used in) Financing Activities -103 K USD -100%
Net Cash Provided by (Used in) Investing Activities -2 K USD +60%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 14.4 M shares -2.91%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.94 M USD -171%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.72 M USD -92.7%
Deferred Tax Assets, Valuation Allowance 38.7 M USD +32.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 39 M USD +33.6%
Operating Lease, Liability 2.29 K USD
Depreciation 162 K USD -3.57%
Payments to Acquire Property, Plant, and Equipment 2 K USD -60%
Property, Plant and Equipment, Gross 1.62 M USD +0.12%
Operating Lease, Liability, Current 419 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 345 K USD -4.17%
Lessee, Operating Lease, Liability, to be Paid, Year One 445 K USD
Deferred Income Tax Expense (Benefit) 584 K USD -24.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 375 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 309 K USD -14.2%
Deferred Tax Assets, Operating Loss Carryforwards 27.6 M USD +22%
Unrecognized Tax Benefits 1.32 M USD +54.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 308 K USD +157%
Additional Paid in Capital 148 M USD +1.9%
Share-based Payment Arrangement, Expense 2.24 M USD -16.4%
Operating Leases, Future Minimum Payments, Due in Three Years 409 K USD
Operating Leases, Future Minimum Payments Due 860 K USD +2.38%
Interest Expense 5 K USD +66.7%